Important Safety Information
Banner: Living with Lymphoma
Join the Living With Lymphoma Community
A Genentech and Biogen Idec program
The Living With Lymphoma program is a source of support, education, and inspiration. But Living With Lymphoma is more than a patient support program. It’s a community made up of people from all corners of the non-Hodgkin’s lymphoma world. We’ve partnered with patients, their loved ones, oncologists, and nurses to bring you helpful information and resources.
Sign up today to receive:
- Ongoing education about some possible treatment options and practical tips for living with lymphoma
- A personalized Care Team Discussion Guide
- A series of customized e-mails
- Newsletters featuring members of the lymphoma community, including former NFL running back Merril Hoge
You must be 18 years of age or older to register. If you are under the age of 18 and wish to register to obtain further information, then your parent or legal guardian must register to obtain the information.
Meet some members of the Living With Lymphoma community
“Within non-Hodgkin’s lymphoma there are at least 30 different types. These different lymphomas are separate with respect to their prognosis and treatment. So that is probably the biggest and most important thing for patients to know—which specific type they have.” — John P. Leonard, MD, Hematologist
“There was never any question that I would be an active participant in my husband Rick’s treatment and recovery. We knew we would deal with this as a family. I made plans to attend every doctor appointment and to be present for any future medical tests Rick would have. Each family must find their own path. But you should know that those of us who have gone before are cheering you on. Stay informed, take charge of your medical information, ask questions, and stay hopeful.” —Sue, caregiver
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
Indications and Important Safety Information
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
People with serious infections should not receive RITUXAN.
Important Safety Information:
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor
Please see full Prescribing Information, including Medication Guide.
